Health Care - As enacted, authorizes a physician to perform stem cell therapy or regenerative medicine therapy that is not approved by the United States food and drug administration if such therapy is used for a treatment or procedure that is within the scope of practice of the physician; makes related changes. - Amends TCA Title 63 and Title 68.

HB 2246 regulates stem cell therapies in Tennessee by requiring physicians performing such treatments (for orthopedics, wound care, or pain management) to source stem cells only from facilities registered with the FDA and accredited by specific organizations like the National Marrow Donor Program. The bill mandates that facilities provide detailed accreditation documentation to physicians and include a post-thaw viability report for each cell batch. Physicians must also disclose in all advertisements that the therapy is not FDA-approved and encourage patients to consult their primary care provider. The law explicitly excludes stem cell therapies derived from fetal or embryonic sources.